Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zota Health CareNSE:ZOTA -1.33%78 EV-to-EBITDA is 621.60 as of Sep. 11, 2026, which is 450% above its 10-year median of 113.00. GuruFocus rates NSE:ZOTA with a GF Score™ of 78/100 and a GF Value™ of ₹1,735.48 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 403 Biotechnology companies, Zota Health Care ranks worse than 98.01% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Zota Health Care's enterprise value is ₹34,753 Mil.
Zota Health Care's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ₹56 Mil. Therefore, Zota Health Care's EV-to-EBITDA for today is 621.60.
The historical rank and industry rank for Zota Health Care's EV-to-EBITDA or its related term are showing as below:
NSE:ZOTA'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -807.55 Med: 113 Max: 5879.63
Current: 621.6
During the past 13 years, the highest EV-to-EBITDA of Zota Health Care was 5879.63. The lowest was -807.55. And the median was 113.00.
NSE:ZOTA's EV-to-EBITDA is ranked worse than 98.01% of 403
companies
in the Biotechnology industry
Industry Median: 13.21
vs NSE:ZOTA: 621.60
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Zota Health Care (NSE:ZOTA) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Zota Health Care's PE Ratio (TTM) for today is calculated as:
Zota Health Care's share price for today is ₹1099.50.
Zota Health Care's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-31.410.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Zota Health Care's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:ZOTA vs VRTX, REGN, MRNA: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Zota Health Care's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zota Health Care EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zota Health Care's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Zota Health Care's EV-to-EBITDA falls into.
Zota Health Care's current Enterprise Value is ₹34,753 Mil.
Zota Health Care's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹56 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zota Health Care (NSE:ZOTA) has a EV-to-EBITDA of 621.60 as of Sep. 11, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Zota Health Care. This is 450% above median its historical median of 113.00. According to the industry distribution chart, Zota Health Care ranks #395 out of 403 companies in the Biotechnology industry, placing it in the top 98%.
Is Zota Health Care's EV-to-EBITDA too high?
Zota Health Care's current EV-to-EBITDA of 621.60 is 450% above median its 10-year median of 113.00. The Biotechnology industry median EV-to-EBITDA is 13.21. Zota Health Care's value of 621.60 is 4605.5% above this industry median. Based on the distribution chart, Zota Health Care ranks #395 out of 403 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Zota Health Care has a GF Score™ of 78/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zota Health Care's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zota Health Care ranks #395 out of 403 companies for EV-to-EBITDA. This places Zota Health Care in the lower half of its industry. The industry median EV-to-EBITDA is 13.21. Zota Health Care's value of 621.60 is 4605.5% above this benchmark. While the company's 10-year median is 113.00 vs. the industry median of 13.21, Zota Health Care has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.21, based on 403 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zota Health Care's current EV-to-EBITDA of 621.60 is 4605.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Zota Health Care. For the Biotechnology industry, the median EV-to-EBITDA is 13.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zota Health Care's current EV-to-EBITDA is 621.60, which is 450% above median its own 10-year median of 113.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zota Health Care stock overvalued right now?
Based on GuruFocus' analysis, Zota Health Care (NSE:ZOTA) is currently considered Possible Value Trap. The stock's GF Value™ is ₹1,735.48, compared to a current price of ₹1,099.50 — trading 36.6% below its estimated fair value. The current EV-to-EBITDA is 621.60, which is 450% above median its 10-year median of 113.00 and 4605.5% above the Biotechnology industry median of 13.21. Zota Health Care's overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Zota Health Care (NSE:ZOTA), the current EV-to-EBITDA is 621.60 as of Sep. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zota Health Care (NSE:ZOTA) Overvalued in 2026?
Based on GuruFocus' analysis, Zota Health Care stock appears to be undervalued.
The current stock price of ₹1,099.50 is trading 36.6% below its estimated GF Value™ of ₹1,735.48.
GuruFocus considers Zota Health Care to be Possible Value Trap.
Key valuation signals for NSE:ZOTA:
EV-to-EBITDA: 621.60 (450% above median its 10-year median of 113.00)
GF Value™: ₹1,735.48 vs. price of ₹1,099.50 (36.6% below fair value)
Industry Position: 4605.5% above the Biotechnology median (#395 of 403)
No single metric tells the full story. See the NSE:ZOTA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zota Health Care Ltd is engaged in the manufacturing, trading, and export of pharmaceutical products. The company caters to both domestic and international markets. It offers a vast range of pharmaceutical, nutraceutical, ayurvedic, and OTC products in India and overseas as well.
78GF Score
Get the complete analysis for NSE:ZOTA
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ZOTA has been successfully added to your 
